CENTRAL-NERVOUS-SYSTEM EFFECTS OF SUBDISSOCIATIVE DOSES OF (S)-KETAMINE ARE RELATED TO PLASMA AND BRAIN CONCENTRATIONS MEASURED WITH POSITRON EMISSION TOMOGRAPHY IN HEALTHY-VOLUNTEERS

被引:101
作者
HARTVIG, P
VALTYSSON, J
LINDNER, KJ
KRISTENSEN, J
KARLSTEN, R
GUSTAFSSON, LL
PERSSON, J
SVENSSON, JO
OYE, I
ANTONI, G
WESTERBERG, G
LANGSTROM, B
机构
[1] UNIV UPPSALA HOSP,DEPT ANESTHESIOL & INTENS CARE,S-75185 UPPSALA,SWEDEN
[2] KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT CLIN PHARMACOL,S-75185 UPPSALA,SWEDEN
[3] UNIV OSLO,SCH MED,DEPT PHARMACOL,OSLO,NORWAY
关键词
D O I
10.1016/0009-9236(95)90194-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Plasma concentrations, maximum regional brain concentrations, and specific regional binding in the brain after administration of 0, 0.1, and 0.2 mg/kg doses of (S)-ketamine were measured in a randomized, double-blind, crossover study in five volunteers and were related to induced effects such as analgesia, amnesia, and mood changes. Specific binding in the brain was assessed by simultaneous administration of (S)-[N-methyl-C-11]ketamine quantified by positron emission tomography. High radioactivities in the brain corresponded to regional distribution of N-methyl-D-aspartate receptor complexes. A significant and dose-dependent reduction of binding was measured as a result of displacement of (S)-[N-methyl-C-11]ketamine. Memory impairment and psychotomimetic effects were related to dose, plasma concentration 4 minutes after administration, and decreased regional binding of (S)-ketamine in the brain and were consistently seen at plasma and maximum regional brain (S)-ketamine concentrations higher than 70 and 500 ng/ml, respectively. The magnitude of specific binding of (S)-ketamine, measured with positron emission tomography, can be related directly to drug effects.
引用
收藏
页码:165 / 173
页数:9
相关论文
共 22 条
[11]   INVIVO CHARACTERIZATION OF MYOCARDIUM MUSCARINIC RECEPTORS BY POSITRON EMISSION TOMOGRAPHY [J].
MAZIERE, M ;
COMAR, D ;
GODOT, JM ;
COLLARD, P ;
CEPEDA, C ;
NAQUET, R .
LIFE SCIENCES, 1981, 29 (23) :2391-2397
[12]  
MAZIERE M, 1981, GABA BENZODIAZEPINE, P273
[13]   TACRINE RESTORES CHOLINERGIC NICOTINIC RECEPTORS AND GLUCOSE-METABOLISM IN ALZHEIMER PATIENTS AS VISUALIZED BY POSITRON EMISSION TOMOGRAPHY [J].
NORDBERG, A ;
LILJA, A ;
LUNDQVIST, H ;
HARTVIG, P ;
AMBERLA, K ;
VIITANEN, M ;
WARPMAN, U ;
JOHANSSON, M ;
HELLSTROMLINDAHL, E ;
BJURLING, P ;
FASTH, KJ ;
LANGSTROM, B ;
WINBLAD, B .
NEUROBIOLOGY OF AGING, 1992, 13 (06) :747-758
[14]  
OYE I, 1991, NMDA RECEPTOR RELATED AGENTS : BIOCHEMISTRY, PHARMACOLOGY AND BEHAVIOR, P381
[15]  
OYE L, 1990, J PHARMACOL EXP THER, V260, P1209
[16]   BENEFICIAL-EFFECTS OF KETAMINE IN A CHRONIC PAIN STATE WITH ALLODYNIA, POSSIBLY DUE TO CENTRAL SENSITIZATION [J].
PERSSON, J ;
AXELSSON, G ;
HALLIN, RG ;
GUSTAFSSON, LL .
PAIN, 1995, 60 (02) :217-222
[17]  
PONTO LLB, 1992, CLIN PHARMACOKINET, V22, P211
[18]   A 2-COMPARTMENT DESCRIPTION AND KINETIC PROCEDURE FOR MEASURING REGIONAL CEREBRAL [C-11] NOMIFENSINE UPTAKE USING POSITRON EMISSION TOMOGRAPHY [J].
SALMON, E ;
BROOKS, DJ ;
LEENDERS, KL ;
TURTON, DR ;
HUME, SP ;
CREMER, JE ;
JONES, T ;
FRACKOWIAK, RSJ .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1990, 10 (03) :307-316
[19]  
SCHERZ MW, 1993, J MED CHEM, V33, P2421
[20]   PHENCYCLIDINE AND PSYCHOTOMIMETIC SIGMA OPIATES - RECENT INSIGHTS INTO THEIR BIOCHEMICAL AND PHYSIOLOGICAL SITES OF ACTION [J].
SONDERS, MS ;
KEANA, JFW ;
WEBER, E .
TRENDS IN NEUROSCIENCES, 1988, 11 (01) :37-40